Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. 2010

Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
Microbiology Department, National Autonomous University of Honduras (UNAH), Tegucigalpa, Honduras. wendy.murillo@smi.se

BACKGROUND Transmitted drug resistance (TDR) reduces the efficacy of antiretroviral treatment and is a public health concern. OBJECTIVE To gain insight in the epidemiology of TDR in Honduras by evaluating the amount of TDR in a representative sample of newly diagnosed individuals and by determining whether these are recent or established infections. METHODS Two hundred treatment-naïve, newly diagnosed HIV-positive individuals representing different population groups (general population, Garifunas ethnic group, female sex workers and men who have sex with men) and different geographic regions were enrolled during April 2004-April 2007. The HIV-1 pol gene was sequenced to identify drug-resistant mutations and TDR was scored as recommended by the WHO. Specimens were classified as recent or established infections using the BED assay. RESULTS Among 200 samples analyzed from Honduran patients the prevalence of TDR was 7% (95% CI: 3.9-11.5%), 5% for non-nucleoside reverse transcriptase inhibitors (NNRTIs), 3% for nucleoside reverse transcriptase inhibitors (NRTIs) and 0.5% for protease inhibitors (PIs). Testing of these samples with the BED assay revealed that 12% of the specimens were associated with recent infections. TDR was significantly more common in specimens with recent infection (21%) than established infection (5%) (p=0.016). CONCLUSIONS The prevalence of TDR in Honduras was moderate (7%). The percentage of specimens who were recently infected was low (12%), suggesting that late HIV diagnosis is common. The TDR prevalence was higher in recent than in established infections, which may indicate that TDR is increasing over time. The higher prevalence of NNRTI and NRTI mutations as compared to PI mutations is probably due to a broader and longer use of these drugs in Honduras.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D006721 Honduras A country in CENTRAL AMERICA, bordering the Caribbean Sea, between GUATEMALA and NICARAGUA and bordering the Gulf of Fonseca (North Pacific Ocean), between EL SALVADOR and NICARAGUA.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
February 2013, AIDS research and human retroviruses,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
April 2011, AIDS (London, England),
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
October 2015, Journal of medical virology,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
December 2020, Journal of medical virology,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
March 2020, AIDS (London, England),
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
February 2011, Southern medical journal,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
December 2011, AIDS research and human retroviruses,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
January 2010, AIDS research and human retroviruses,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
March 2020, Journal of global antimicrobial resistance,
Wendy Murillo, and Gabriela Paz-Bailey, and Sonia Morales, and Edgar Monterroso, and Mayte Paredes, and Trudy Dobbs, and Bharat S Parekh, and Jan Albert, and Ivette Lorenzana de Rivera
August 2018, Scientific reports,
Copied contents to your clipboard!